CoChat

Current Concepts in Probiotic Safety and Efficacy

Open access

The DOI matches its Crossref record; 159 of the 184 references it cites were found in a registry or an index, and 18 are not checked yet; 108 of the 180 sources its claims cite were checked for support.

Abstract

This review summarizes current knowledge on the efficacy and safety of probiotics, analyzes limitations in clinical safety reporting, and compares regulatory frameworks governing the use of probiotics as dietary supplements, medicinal products, and live biotherapeutics. Particular attention is given to new genomic and computational approaches to safety assessment. Overall, the review emphasizes the need for coordinated regulation, rigorous clinical evidence, and integrated, modern safety assessment strategies to support the responsible expansion of probiotic use.

Verified 2026-11-20 · 18 references not checked yet

Overview

CoChat Summary

## TL;DR

This review argues that probiotics are generally safe for healthy people, but their safety and efficacy are highly strain-, dose-, host-, and context-dependent, with rare but serious harms reported in vulnerable groups. It also emphasizes that next-generation probiotics need stronger genomic, phenotypic, clinical, and regulatory scrutiny, alongside harmonized standards.

## Key findings

  • Probiotics are “generally safe” for healthy individuals, but rare clinically significant adverse events have been reported, including bacteremia and endocarditis, especially in people with implanted devices, impaired barrier function, severe comorbidities, immunodeficiency, or critical illness.
  • The review states that adverse-event data are incomplete: it says the true incidence of probiotic-associated infections is unknown because of lack of systematic reporting and weak post-market harm detection, and that most side effects are described in individual case reports rather than randomized trials.
  • Clinical safety evidence is heterogeneous: the text notes 2 randomized controlled trials, 7 systematic reviews (including case reports), and 1 case report among the cited safety literature, with populations spanning healthy adults, mixed groups, and high-risk patients.
  • A cited analysis of 622 randomized clinical studies found no statistically significant increase in relative risk for total adverse events, including serious ones, with short-term probiotic use versus controls; another report described 93 serious infections with a 15% mortality rate, including fungemia (37.6%), sepsis (31.2%), bacteremia (20.4%), endocarditis, and abscesses.
  • Safety assessment should be strain-specific and multi-level: strain identification, phenotypic antimicrobial susceptibility testing, whole-genome sequencing, in vitro assays, preclinical models, and clinical trials/meta-analyses all contribute, while AI/computational tools are described as supportive but still preliminary/experimental.

## Methods

  • Narrative review of current concepts in probiotic safety, efficacy, regulation, and computational assessment; the abstract states it “summarizes current knowledge,” analyzes limitations in clinical safety reporting, and compares regulatory frameworks.
  • The paper draws on published literature and regulatory documents, including cited safety studies and frameworks from EFSA, FDA, FAO/WHO, and Russian regulations.
  • Main analysis is qualitative synthesis: it contrasts traditional probiotics, next-generation probiotics, and live biotherapeutic products; reviews safety risks, reporting limitations, and genomic/computational screening approaches.

## Limitations

  • The paper states that clinical safety reporting is limited by “lack of systematic reporting on adverse effects” and ineffective post-registration harm detection.
  • It also states that many studies are heterogeneous in design, endpoints, strain identification, dosing, formulations, and populations, which reduces comparability and reproducibility.
  • Evidence for AI/computational approaches is still preliminary and many predictions require external validation and biological confirmation; this is stated in the paper.
  • Evident from the text: the review relies on narrative synthesis rather than a single new experimental dataset, so its conclusions depend on the quality and consistency of the underlying literature.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu18040696

Cites

159 of 184 references verified0 citation errors · 7 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Key safety of new probiotics. Toxicity—evaluation includes testing for virulence factors, toxin production, hemolytic activity, and metabolic deleterious effects like D-lactate production; Microbial Virulence & Pathogenicity—assessing if the microbe has genes for invasion, colonization, or toxin production, even if it is a common gut bacterium; Infectivity—rare cases of infection (bacteremia, fungemia) have occurred, mostly in critically ill or immunocompromised patients; Genetic Stability—the microbe must remain genetically stable over time to ensure it does not evolve harmful traits during production or consumption; Antibiotic Resistance—checking for antibiotic resistance genes and the risk of them transferring to harmful gut bacteria. Probiotics should ideally be susceptible to clinically relevant antibiotics; Regulatory & Quality Standards—compliance of the probiotic with the requirements of “Generally Recognized As Safe” (GRAS) in the US or have “Qualified Presumption of Safety” (QPS) in the EU and safety is also tied to manufacturing standards (c-GMP); Populations and Risk Factors—this group of factors may include several points. Immunocompromised patients: Those with weakened immune systems (e.g., from chemotherapy or HIV) may be unable to clear a “live” probiotic, leading to infection. Critically Ill Patients: Probiotics are often contraindicated for patients in intensive care, those with severe acute pancreatitis, or those using central venous catheters. Infants: Premature infants or those with undeveloped immune functions require extreme caution due to potential microbial invasion and increased gut permeability; Computational technologies—possible areas of use for modern computer technologies (AI, big data, etc.).
Figure 1 Key safety of new probiotics. Toxicity—evaluation includes testing for virulence factors, toxin production, hemolytic activity, and metabolic deleterious effects like D-lactate production; Microbial Virulence & Pathogenicity—assessing if the microbe has genes for invasion, colonization, or toxin production, even if it is a common gut bacterium; Infectivity—rare cases of infection (bacteremia, fungemia) have occurred, mostly in critically ill or immunocompromised patients; Genetic Stability—the microbe must remain genetically stable over time to ensure it does not evolve harmful traits during production or consumption; Antibiotic Resistance—checking for antibiotic resistance genes and the risk of them transferring to harmful gut bacteria. Probiotics should ideally be susceptible to clinically relevant antibiotics; Regulatory & Quality Standards—compliance of the probiotic with the requirements of “Generally Recognized As Safe” (GRAS) in the US or have “Qualified Presumption of Safety” (QPS) in the EU and safety is also tied to manufacturing standards (c-GMP); Populations and Risk Factors—this group of factors may include several points. Immunocompromised patients: Those with weakened immune systems (e.g., from chemotherapy or HIV) may be unable to clear a “live” probiotic, leading to infection. Critically Ill Patients: Probiotics are often contraindicated for patients in intensive care, those with severe acute pancreatitis, or those using central venous catheters. Infants: Premature infants or those with undeveloped immune functions require extreme caution due to potential microbial invasion and increased gut permeability; Computational technologies—possible areas of use for modern computer technologies (AI, big data, etc.).CC BY · PubMed Central
Figure 2 A brief flowchart of the regulation process for new probiotics.
Figure 2 A brief flowchart of the regulation process for new probiotics.CC BY · PubMed Central

Verification

Claims the paper makes

66 Valid · 7 Not valid · 42 Not checked · 71 Own results and interpretations

107 more claims · 48 with their cited sources checked

Create a free account to see all 186 claims and to verify the 6 references still open.

See all claims — free account
  • It may state two separate claims as one. 61
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Citations

Cites

Cited by

See all 31

Metadata

Authors
Churin, A. A., Sokolyanskaya, L. O., Lukina, A. P., & Karnachuk, O. V.
Affiliations
National Research Tomsk State University (RU)
Corresponding author
Churin, Alexey A.
Venue
Nutrients
Publisher
MDPI AG
Published
2026-02-21
Volume
18
Issue
4
Pages
696
ISSN
2072-6643 (ISSN-L)
OpenAlex
W7130931644
Cited by
31
References
175
Citations by year
2026: 31
FWCI
16.68
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
Russian Science Foundation (25-24-00493)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
probiotics, probiotic safety, probiotic efficacy, adverse events, probiotic regulation, live biotherapeutic products, dietary supplements, safety assessment, microbiome
MeSH terms
Humans, Dietary Supplements, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.